- Home
- SLSR vs AQST Comparison
SLSR vs AQST Comparison
Compare SLSR & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- AQST
- Stock Information
- Founded
- SLSR 2018
- AQST 2004
- Country
- SLSR Canada
- AQST United States
- Employees
- SLSR N/A
- AQST N/A
- Industry
- SLSR
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- SLSR
- AQST Health Care
- Exchange
- SLSR NYSE
- AQST Nasdaq
- Market Cap
- SLSR 462.9M
- AQST 502.6M
- IPO Year
- SLSR N/A
- AQST 2018
- Fundamental
- Price
- SLSR $3.02
- AQST $4.51
- Analyst Decision
- SLSR Strong Buy
- AQST Strong Buy
- Analyst Count
- SLSR 2
- AQST 7
- Target Price
- SLSR $7.50
- AQST $9.43
- AVG Volume (30 Days)
- SLSR 43.8K
- AQST 1.7M
- Earning Date
- SLSR 11-12-2024
- AQST 11-04-2024
- Dividend Yield
- SLSR N/A
- AQST N/A
- EPS Growth
- SLSR N/A
- AQST N/A
- EPS
- SLSR N/A
- AQST N/A
- Revenue
- SLSR N/A
- AQST $58,900,000.00
- Revenue This Year
- SLSR N/A
- AQST $18.45
- Revenue Next Year
- SLSR N/A
- AQST N/A
- P/E Ratio
- SLSR N/A
- AQST N/A
- Revenue Growth
- SLSR N/A
- AQST 22.56
- 52 Week Low
- SLSR $0.03
- AQST $1.84
- 52 Week High
- SLSR $0.19
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- SLSR 74.09
- AQST 40.86
- Support Level
- SLSR $2.23
- AQST $4.36
- Resistance Level
- SLSR $2.44
- AQST $4.88
- Average True Range (ATR)
- SLSR 0.16
- AQST 0.37
- MACD
- SLSR 0.08
- AQST -0.07
- Stochastic Oscillator
- SLSR 85.57
- AQST 12.20
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.